Schnitzer Steel Industries Inc

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.  The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.  Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.  Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Schnitzer Steel Reports Q3 Loss, Focuses on Strategic Growth

Schnitzer Steel is navigating a challenging market landscape with strategic initiatives aimed at improving margins and capitalizing on favorable demand trends. The company is focused on cost control, productivity improvements, and strategic investments to position itself for recovery and growth in a transitioning industry.

Schnitzer Steel Industries Inc doubles EBITDA in Q4 2024

Schnitzer Steel Industries Inc delivered a robust performance in Q4 2024, driven by increased sales volumes and cost-saving initiatives amidst challenging market conditions.
The company showcased strengths in managing operational efficiency, capitalizing on favorable market trends, and maintaining financial flexibility with manageable debt levels.
While facing challenges such as market headwinds and high capital expenditures, Schnitzer Steel has opportunities to further enhance operational efficiency, capitalize on market trends, and drive revenue growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Radius Recycling, Inc. engages in the recycling of ferrous and nonferrous scrap metal and manufacture of finished steel products. The company was founded by Sam Schnitzer in 1906 and is headquartered in Portland, OR.

The FDA has approved updates to Radius Health Inc's (NASDAQ: RDUS) Tymlos label, including removing the boxed warning regarding the risk of osteosarcoma, a type of cancer. The removal of the boxed warning comes after a thorough regulatory review of long-term post-marketing data in Tymlos and the parathyroid hormone (PTH) class of drugs.

FDA Approves Update On Radius Health's Tymlos label

BOSTON, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYMLOS label, including the removal of the boxed warning regarding the risk of osteosarcoma.

Radius Announces Update on TYMLOS® (abaloparatide) Label

Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.

Radius (RDUS) Announces Data on Breast Cancer Drug, Abalo-TDS

A closer look at the clinical trial results that drove the stock up in October was a little disappointing.

Why Radius Health Stock Is Getting Pummeled Today

The Menarini Group and Radius Health Inc (NASDAQ: RDUS) have provided details on the elacestrant data from the EMERALD Phase 3 trial presented at the San Antonio Breast Cancer Symposium. As previously announced, the study met its two primary endpoints: progression-free survival (PFS) in the overall population and PFS in patients with tumors harboring Estrogen Receptor 1 (ESR 1) mutations.

Radius Health Reveals Detailed Elacestrant Data From Late-Stage Breast Cancer Trial

FLORENCE, Italy and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) provided details on the elacestrant data from the EMERALD trial following the positive results presented today at the San Antonio Breast Cancer Symposium (SABCS). The data was presented as a “Late Breaker” and shared in an oral presentation by Dr. Aditya Bardia, MD.

Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced phase 3 topline results from the wearABLe study evaluating the non-inferiority (NI) of abaloparatide transdermal system (abalo-TDS) compared to abaloparatide subcutaneous injection (TYMLOS) in postmenopausal women with osteoporosis.

Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis

BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET to cover the below:

Radius Health to Host Conference Call Today, Wednesday, December 8, 2021

Radius (RDUS) reports a year-over-year wider Q3 loss and misses on sales. The company also lowers guidance for lead drug Tymlos.

Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines

Radius Pharmaceuticals, Inc. (RDUS) CEO Kelly Martin on Q3 2021 Results - Earnings Call Transcript

Radius Health (RDUS) delivered earnings and revenue surprises of -74.07% and -7.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Radius Health (RDUS) Reports Q3 Loss, Misses Revenue Estimates

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its results for the third quarter ended September 30, 2021.

Radius Health, Inc.: Third Quarter 2021 Results

Radius Health (NASDAQ:RDUS) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement.

Earnings Outlook For Radius Health

Axsome Therapeutics

Editas Medicine

Viatris

Let us look at four drug/biotech companies, VTRS, RDUS, AXSM and EDIT, which are gearing up for their earnings release.

Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & More

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Radius Health (RDUS) Q3 Earnings Expected to Decline

BOSTON, Oct. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday, Oct. 20, by Radius Health, Inc. (NASDAQ: RDUS), please note that the dial-in numbers were listed incorrectly. The correct dial-in numbers are (866) 323-7965 for domestic calls and (346) 406-0961 for international calls. The conference ID remains the same, 9322858. The corrected release appears below:

CORRECTING and REPLACING -- Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a company update.

Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021

Positive clinical-trial results for a late-stage breast cancer treatment are pushing the stock up.

Why Radius Health Stock Is Exploding Higher Today

The Menarini Group and Radius Health Inc (NASDAQ: RDUS) have announced topline results from the EMERALD Phase 3 study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer patients. There were two primary endpoints: progression-free survival (PFS) in the overall population and PFS in patients with tumors harboring estrogen receptor 1 (ESR1) mutations.

Why Are Radius Health Shares Soaring Today?

FLORENCE, Italy and BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- the Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced positive topline results from the EMERALD study.

Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.

Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal

The stock price of Radius Health Inc (NASDAQ: RDUS) increased by over 12% this past week. This is why it happened.

RDUS Stock: Why The Price Increased This Week

BOSTON, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced positive topline results from the ATOM study evaluating abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis.

Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis

Radius Health (RDUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Radius Health (RDUS) Stock Jumps 7.1%: Will It Continue to Soar?

BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), provided a business update.

News for Schnitzer Steel Industries Inc Stock (RDUS)